Summit Therapeutics Inc.
SMMT
$25.26
$1.305.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.59M | 14.44M | 20.39M | 13.97M | 11.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -205.00K | 264.00K | -159.00K | -- |
| Total Operating Expenses | 66.85M | 65.61M | 58.38M | 44.61M | 42.39M |
| Operating Income | -66.85M | -65.61M | -58.38M | -44.61M | -42.39M |
| Income Before Tax | -62.91M | -61.20M | -56.25M | -60.39M | -43.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.91M | -61.20M | -56.25M | -60.39M | -43.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.91M | -61.20M | -56.25M | -60.39M | -43.47M |
| EBIT | -66.85M | -65.61M | -58.38M | -44.61M | -42.39M |
| EBITDA | -66.83M | -65.59M | -58.36M | -44.59M | -42.36M |
| EPS Basic | -0.09 | -0.08 | -0.08 | -0.09 | -0.06 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.05 | -0.04 | -0.04 |
| EPS Diluted | -0.09 | -0.09 | -0.08 | -0.09 | -0.06 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.05 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 738.08M | 737.50M | 726.66M | 707.90M | 701.79M |
| Average Diluted Shares Outstanding | 738.08M | 737.50M | 726.66M | 707.90M | 701.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |